The plant cannabinoid Δ 9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice

British Journal of Pharmacology

Volumn 160, Issue 3, 2010, Pages 677-687

  Bolognini, Daniele ^a,b   Costa, Barbara ^c   Maione, Sabatino ^d   Comelli, Francesca ^c   Marini, Pietro ^a   Di Marzo, Vincenzo ^e   Parolaro, Daniela ^b   Ross, Ruth A ^a   Gauson, Lisa A ^a   Cascio, Maria G ^a   Pertwee, Roger G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e CNR   (Italy)

Author keywords

9 Tetrahydrocannabivarin; Carrageenan; CB 1 receptor; CB 2 receptor; CP55940; Formalin; Inflammation; Pain; Pertussis toxin

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CYCLIC AMP; DELTA 9 TETRAHYDROCANNABIVARIN; FORSKOLIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); PERTUSSIS TOXIN; RIMONABANT; UNCLASSIFIED DRUG; DRUG DERIVATIVE; TETRAHYDROCANNABINOL; TETRAHYDROCANNABIVARIN 9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHO CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HAMSTER; HYPERALGESIA; INFLAMMATION; MOUSE; NONHUMAN; PAIN; PAW EDEMA; PRIORITY JOURNAL; PROTEIN BINDING; SPLEEN; ANIMAL; C57BL MOUSE; CELL LINE; CRICETULUS; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; EDEMA; HUMAN; MALE; MEMBRANE; METABOLISM; METHODOLOGY; PAIN ASSESSMENT;

ANIMALS; CELL LINE, TRANSFORMED; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; EDEMA; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; INFLAMMATION; MALE; MEMBRANES; MICE; MICE, INBRED C57BL; PAIN; PAIN MEASUREMENT; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SPLEEN; TETRAHYDROCANNABINOL;

EID: 77952645077     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00756.x     Document Type: Article

References (40)

1. Abbott FV, Guy ER (1995). Effects of morphine, pentobarbital and amphetamine on formalin-induced behaviours in infant rats: sedation versus specific suppression of pain. Pain 62 : 303 312.
2. Alexander SPH, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC). Br J Pharmacol 158 (Suppl 1 S1 S254.
3. 1 agonist. Pain 124 : 175 183.
4. 2) selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol 151 : 1061 1070.
5. Bonhaus DW, Chang LK, Kwan J, Martin GR (1998). Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 287 : 884 888.
6. Buckley NE, McCoy KL, Mezey É, Bonner T, Zimmer A, Felder CC et al. (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. Eur J Pharmacol 396 : 141 149.
7. 50) of an enzymatic reaction. Biochem Pharmacol 22 : 3099 3108.
8. Costa B, Colleoni M, Conti S, Parolaro D, Franke C, Trovato AE et al. (2004). Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol 369 : 294 299.
9. 1 receptors in hippocampal neurons. J Neurosci 21 : 2425 2433.
10. 35S]GTPγS binding in mouse brain cerebellum and piriform cortex membranes. Br J Pharmacol 154 : 1349 1358.
11. Dubuisson D, Dennis SG (1977). The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain 4 : 161 174.
12. Fong TM, Shearman LP, Stribling DS, Shu J, Lao J, Huang CR-R et al. (2009). Pharmacological efficacy and safety profile of taranabant in preclinical species. Drug Dev Res 70 : 349 362.
13. s linkage to the CB1 receptor. J Neurosci 17 : 5327 5333.
14. 2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153 : 319 334.
15. Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988). A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32 : 77 88.
16. Hillard CJ, Manna S, Greenberg MJ, Dicamelli R, Ross RA, Stevenson LA et al. (1999). Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther 289 : 1427 1433.
17. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54 : 161 202.
18. Kenakin T (1997). Pharmacologic Analysis of Drug-receptor Interaction. Lipincott - Raven Publishers
19. Kenakin T (2001). Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15 : 598 611.
20. 9-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum. Br J Pharmacol 154 : 204 215.
21. Maione S, De Petrocellis L, de Novellis V, Schiano Moriello A, Petrosino S, Palazzo E et al. (2007). Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 150 : 766 781.
22. Mallat A, Teixeira-Clerc F, Deveaux V, Lotersztajn S (2007). Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opin Ther Targets 11 : 403 409.
23. 2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242. Br J Pharmacol 158 : 382 391.
24. 2 receptors. Pharmacol Ther 74 : 129 180.
25. Pertwee RG (1999). Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6 : 635 664.
26. Pertwee RG (2001). Cannabinoid receptors and pain. Prog Neurobiol 63 : 569 611.
27. 9- tetrahydrocannabivarin. Br J Pharmacol 153 : 199 215.
28. Pertwee RG (2009). Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156 : 397 411.
29. 9-tetrahydrocannabivarin in mice in vivo. Br J Pharmacol 150 : 586 594.
30. Riedel G, Fadda P, McKillop-Smith S, Pertwee RG, Platt B, Robinson L (2009). Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol 156 : 1154 1166.
31. Ross RA (2009). The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 30 : 156 163.
32. 2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 126 : 665 672.
33. 8- tetrahydrocannabinol at cannabinoid receptors. Br J Pharmacol 128 : 735 743.
34. Sawynok J, Liu XJ (2004). The formalin test: characteristics and usefulness of the model. Rev Analg 7 : 145 163.
35. 2 receptors. Calcif Tissue Int 80 : 50 59.
36. 2 receptor antagonist. Br J Pharmacol 146 : 917 926.
37. Viganò D, Rubino T, Di Chiara G, Ascari I, Massi P, Parolaro D (2003). μ Opioid receptor signaling in morphine sensitization. Neuroscience 117 : 921 929.
38. Whiteside GT, Lee GP, Valenzano KJ (2007). The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr Med Chem 14 : 917 936.
39. 2 receptor? Br J Pharmacol 149 : 145 154.
40. Zhang M, Martin BR, Adler MW, Razdan RJ, Kong W, Ganea D et al. (2009). Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke. J Neuroimmune Pharmacol 4 : 249 259.